Blood and Lymphatic Cancer Targets and Therapy
译名:血液与淋巴癌:靶点与治疗
Blood and Lymphatic Cancer-Targets and Therapy
3-5
2026
影响因子区间
—
平台估算
58%
2025
中国作者发文占比
40000000 IRR;600 USD
收费
期刊简介:Blood and Lymphatic Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient. Blood and Lymphatic Cancer: Targets and Therapy will no longer consider meta-analyses for publication. Specific topics covered in the journal include: Epidemiology, detection and screening Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing anticancer agents, including combination therapies Radiation, surgery, bone marrow transplantation Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations
【译文】血液和淋巴癌:目标和治疗是一本国际同行评审、开放获取期刊,专注于血液和淋巴癌研究、治疗目标的确定以及预防性和综合治疗干预措施的最佳使用,以改善癌症患者的结果、提高生存率和生活质量。血液和淋巴癌:目标和治疗将不再考虑发表荟萃分析。该杂志涵盖的具体主题包括: 流行病学、检测和筛查 细胞研究和生物标志物 具有新颖作用机制的生物靶点和药物的鉴定 现有抗癌药物的最佳临床使用,包括联合疗法 放射、手术、骨髓移植 姑息治疗 患者依从性、生活质量、满意度 健康经济评估

| 指标 | 当前值 | 近三年趋势 |
|---|---|---|
| JCR分区 | Q2 | 暂无 |
| 中科院分区 | 2区 | 暂无 |
| 影响因子区间 | 3-5 | 暂无 |